[Federal Register Volume 89, Number 174 (Monday, September 9, 2024)]
[Notices]
[Pages 73102-73103]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-20268]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meetings

    Pursuant to section 1009 of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse, Initial 
Review Group; Career Development Education and Training Study 
Section.
    Date: October 24-25, 2024.
    Time: 9:30 a.m. to 5:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institute of Health, National Institute on Drug 
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual 
Meeting).
    Contact Person: Sindhu Kizhakke Madathil, Ph.D., Scientific 
Review Officer, Division of Extramural Research, Scientific Review 
Branch, National Institute on Drug Abuse, NIH, 301 North Stonestreet 
Avenue, MSC 6021, Bethesda, MD 20892, (301) 827-5702, 
[email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Transformative Research on the Basic Mechanisms of 
Polysubstance Use in Addiction.
    Date: November 1, 2024.
    Time: 9:30 a.m. to 5:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institute of Health, National Institute on Drug 
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual 
Meeting).
    Contact Person: Sindhu Kizhakke Madathil, Ph.D., Scientific 
Review Officer, Division of Extramural Research, Scientific Review 
Branch, National Institute on Drug Abuse, NIH, 301 North Stonestreet 
Avenue, MSC 6021, Bethesda, MD 20892, (301) 827-5702, 
[email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Addressing HIV in Highest Risk Sexual and Gender 
Minorities.
    Date: November 4, 2024.
    Time: 12:30 p.m. to 4:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institute of Health, National Institute on Drug 
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual 
Meeting).
    Contact Person: Shareen Amina Iqbal, Ph.D., Scientific Review 
Officer, Division of Extramural Research, Scientific Review Branch, 
National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, 
MSC 6021, Bethesda, MD 20892, (301) 443-4577, [email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Functional Validation and/or Characterization of 
Genes or Variants Implicated in Substance Use Disorders and NIDA 
Animal Genomics Program.
    Date: November 19, 2024.
    Time: 10:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institute of Health, National Institute on Drug 
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual 
Meeting).
    Contact Person: Devon Rene Oskvig, Ph.D., Scientific Review 
Officer, Division of Extramural Research, Scientific Review Branch, 
National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, 
MSC 6021, Bethesda, MD 20892, (301) 402-6965, [email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug 
Abuse Scientist Development Award for Clinicians, Scientist 
Development Awards, and Research Scientist Awards; 93.278, Drug 
Abuse National Research Service Awards for Research Training; 
93.279, Drug Abuse and Addiction Research Programs, National 
Institutes of Health, HHS)


[[Page 73103]]


    Dated: September 4, 2024
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-20268 Filed 9-6-24; 8:45 am]
BILLING CODE 4140-01-P